RxDoctor Payments Data

Charles Johnson, MD

Ophthalmology · Angleton, TXNPI 1154371979

Payments from drug & device makers

$704in general payments, 2019–2025

Across 29 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$241
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$103
  • Novartis$70
  • Bausch & Lomb Americas Inc.$63
  • Harrow Eye, LLC$58
  • Tarsus Pharmaceuticals, Inc.$44
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$704 in reported general payments places this provider in the 30th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$466,880
Medicare patients
1,273
Services billed
4,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine101$116,830
LumiganBimatoprost79$50,931
Cyclosporine54$27,581
CombiganBrimonidine Tartrate/Timolol47$19,038
VyzultaLatanoprostene Bunod39$15,109
XiidraLifitegrast13$14,312
Prednisolone Acetate421$13,057
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol60$13,019
Loteprednol Etabonate90$12,212
Latanoprost1,033$12,015
RocklatanNetarsudil Mesylat/Latanoprost14$11,171
Travoprost40$8,224
Ketorolac Tromethamine362$6,411
RhopressaNetarsudil Mesylate11$5,699
Alphagan PBrimonidine Tartrate13$5,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$30$191,802240 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$63$29,42052 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Alrex$103$16,331103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Angleton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →